Sol-Gel Technologies Net Common Equity Issued/Repurchased 2016-2024 | SLGL
Sol-Gel Technologies net common equity issued/repurchased from 2016 to 2024. Net common equity issued/repurchased can be defined as the net dollar amount of transactions to issue and repurchase common stock.
Sol-Gel Technologies Annual Net Common Equity Issued/Repurchased
(Millions of US $) |
| 2023 |
$22 |
| 2022 |
$0 |
| 2021 |
$0 |
| 2020 |
$26 |
| 2019 |
$11 |
| 2018 |
$79 |
| 2017 |
$N/A |
| 2016 |
$N/A |
| 2015 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.016B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
